Last checked at 8 Feb 2018 17:49
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Â
Total Voting Rights
Â
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
As at 31 January 2018 the Company's issued share capital consists of 475,008,988 Ordinary Shares of 1p each.
The total number of voting rights in the Company is 475,008,988 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Â
For further information:
Â
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Officer Peter Butterfield, Deputy Chief Executive Officer Andrew Franklin, Chief Financial Officer | |
www.alliancepharma.co.uk | |
 Buchanan |  + 44 (0) 20 7466 5000 |
Mark Court / Sophie Wills / Gemma Mostyn-Owen | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock | |
Investec Bank plc | +44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams / Ed Thomas Corporate Broking: Patrick Robb / Rob Baker  |
Â
Notes to editors:
Â
About Alliance Pharma
Â
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Â
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Â